Thromboembolic complications in malignant haematological disorders.

abstract：:Tertiary amine local anesthetics (LAs) are clinically valuable agents for controlling pain and for treating some cardiac arrhythmias. These drugs inhibit conduction of electrical activity by blocking voltage-gated sodium channels. Interestingly, LAs can influence the conduction of electrical activity in heart muscle w...

journal_title：Current vascular pharmacology

authors： Wright SN

更新日期：2003-10-01 00:00:00

abstract：:Paraoxonase-1 (PON-1) is a calcium-dependent enzyme that is synthesized in the liver and then secreted in blood where it is bound to high density lipoprotein (HDL). PON-1 is a hydrolase with a wide range of substrates, including lipid peroxides. It is considered responsible for many of the antiatherogenic properties o...

journal_title：Current vascular pharmacology

authors： Lioudaki S,Verikokos C,Kouraklis G,Ioannou C,Chatziioannou E,Perrea D,Klonaris C

更新日期：2019-01-01 00:00:00

abstract：AIM:To assess the potential differences in the metabolic and cardiovascular disease (CVD) risk between the distinct phenotypes of the Polycystic Ovary Syndrome (PCOS) according to the Rotterdam definition regardless of body mass index (BMI). PATIENTS-METHODS:The study included 300 women; 240 women with PCOS, according...

journal_title：Current vascular pharmacology

authors： Daskalopoulos G,Karkanaki A,Piouka A,Prapas N,Panidis D,Gkeleris P,Athyros VG

更新日期：2015-01-01 00:00:00

abstract：:In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...

journal_title：Current vascular pharmacology

authors： Katsiki N,Athyros VG,Mikhailidis DP,Karagiannis A

更新日期：2012-11-01 00:00:00

abstract：:In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages ...

journal_title：Current vascular pharmacology

authors： Roumeliotis S,Roumeliotis A,Gorny X,Mertens PR

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND:The association between Paget's disease of bone (PDB) and increased cardiovascular (CV) risk has been suggested, but the literature is conflicting. OBJECTIVE:Our study aimed to evaluate two markers of CV risk [common carotid artery intima-media thickness (cIMT) and the aortic pulse wave velocity (PWV)] in p...

journal_title：Current vascular pharmacology

authors： Gaudio A,Zanoli L,Xourafa A,Rapisarda R,Catalano A,Signorelli SS,Castellino P

更新日期：2020-06-09 00:00:00

abstract：:Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are idiopathic, intestinal and systemic inflammatory disorders which are immunologically mediated with the activation of plasma proteolytic cascades. The activation of coagulation in IBD is related to the activity and colonic extension of t...

journal_title：Current vascular pharmacology

authors： Stadnicki A

更新日期：2012-09-01 00:00:00

abstract：:There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic ...

journal_title：Current vascular pharmacology

authors： Satoh S,Ikegaki I,Kawasaki K,Asano T,Shibuya M

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...

journal_title：Current vascular pharmacology

authors： Rubboli A,Patti G

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:The most common complications of chronic kidney disease (CKD) are hypertension and cardiovascular (CV) disorders. Renalase is produced and released by the kidney and also cardiomyocytes. Renalase deficiency was claimed to be responsible for hypertension and CV complication in CKD. There are contradictory dat...

journal_title：Current vascular pharmacology

authors： Malyszko J,Koc-Zorawska E,Zorawski M,Kozminski P,Zbroch E,Rysz J,Banach M,Malyszko JS

更新日期：2015-01-01 00:00:00

abstract：:The "pleiotropic" effects of statins have been the centre of a considerable research activity. Among the numerous experimental and clinical studies of this field, some focused on the effects of statins on blood pressure (BP), while others reported data on BP together with other parameters. Some of the animal or human ...

journal_title：Current vascular pharmacology

authors： Sarafidis PA,Kanaki AI,Lasaridis AN

更新日期：2007-04-01 00:00:00

abstract：:Non-fasting triglycerides are measured at any time within up to 8 h (14 h) after any normal meal, while postprandial triglycerides are measured at a fixed time point within up to 8 h (14 h) of a standardised fat tolerance test. The simplest possible way of evaluating remnant cholesterol is non-fasting/postprandial tot...

journal_title：Current vascular pharmacology

authors： Nordestgaard BG,Freiberg JJ

更新日期：2011-05-01 00:00:00

abstract：:Aldosterone, a steroid hormone with mineralocorticoid activity, is far more than merely a salt-and-water hormone. Aldosterone has a number of non-classical, mineralocorticoid receptor (MR)-mediated actions, including tissue remodeling, modulation of vascular tone and stimulating inflammation and fibrosis, which may fu...

journal_title：Current vascular pharmacology

authors： Waanders F,de Vries LV,van Goor H,Hillebrands JL,Laverman GD,Bakker SJ,Navis G

更新日期：2011-09-01 00:00:00

abstract：INTRODUCTION:Diabetes mellitus (DM) is one of the most common diseases worldwide. Its adverse effects on several body organs, have made treatment of DM a priority. One of the most serious complications of DM is diabetic nephropathy (DN). OBJECTIVE:The aim of this review is to critically discuss available data on the p...

journal_title：Current vascular pharmacology

authors： Papademetriou V,Alataki S,Stavropoulos K,Papadopoulos C,Bakogiannis K,Tsioufis K

更新日期：2020-01-01 00:00:00

abstract：:This essay focuses on nine important lessons learned during more than thirty years of endothelial research. They include: the danger of hiding behind a word, the confusion generated by abbreviations, the need to define the physiological role of the response studied, the local role of endothelium- dependent responses, ...

journal_title：Current vascular pharmacology

authors： Vanhoutte PM

更新日期：2016-01-01 00:00:00

abstract：:Post-transplant diabetes mellitus (PTDM) and dyslipidaemia are the most common metabolic complications in kidney transplant recipients (KTR). They are associated with a higher risk of lower graft function and survival, as well as an increased risk of cardiovascular disease (CVD). The aim of this review is to provide c...

journal_title：Current vascular pharmacology

authors： Anagnostis P,Paschou SA,Spartalis E,Sarno G,De Rosa P,Muscogiuri G

更新日期：2020-01-01 00:00:00

abstract：:Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...

journal_title：Current vascular pharmacology

authors： Dandel M,Hetzer R

更新日期：2010-09-01 00:00:00

abstract：:Matrix metalloproteinases (MMP) comprise a family of at least 25 zinc-dependent endopeptidases that play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after stroke, the dysregulation of MMPs has been described to increase acute neurovascular disruption and cerebral ...

journal_title：Current vascular pharmacology

authors： Lenglet S,Montecucco F,Mach F

更新日期：2015-01-01 00:00:00

abstract：:The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease ...

journal_title：Current vascular pharmacology

authors： Athyros VG,Tziomalos K,Karagiannis A,Mikhailidis DP

更新日期：2009-07-01 00:00:00

abstract：:Aspirin plays a pivotal role in the management of patients with Coronary Artery Disease (CAD) with well-recognised benefits of reducing recurrent myocardial infarction and minimising the risk of stent thrombosis for those undergoing Percutaneous Coronary Intervention (PCI). Dual antiplatelet therapy is mandated for pa...

journal_title：Current vascular pharmacology

authors： Kassimis G,Raina T,Alexopoulos D

更新日期：2019-01-01 00:00:00

abstract：:High-mobility group box-1 (HMGB1) is a nuclear protein that acts as a cytokine when released into the extracellular milieu by necrotic and inflammatory cells, and is involved in inflammatory responses and tissue repair. This protein is released passively during cellular necrosis by almost all cells that have a nucleus...

journal_title：Current vascular pharmacology

authors： Biscetti F,Ghirlanda G,Flex A

更新日期：2011-11-01 00:00:00

abstract：:In the last decade there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VA) and Sudden Cardiac Death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally ...

journal_title：Current vascular pharmacology

authors： El-Sherif N,Pedalino R,Himel H 4th

更新日期：2009-07-01 00:00:00

abstract：: ...

journal_title：Current vascular pharmacology

authors： Guerrero Orriach JL,Ramirez-Fernandez A

更新日期：2019-01-01 00:00:00

abstract：:Reactive oxygen species (ROS) are important signaling molecules in the vasculature. However, when there is imbalance between their occurrence and antioxidant defense mechanisms, ROS can contribute to the vascular abnormalities that lead to hypertension. Evidence accumulated in the last decade strongly supports the not...

journal_title：Current vascular pharmacology

authors： Escobales N,Crespo MJ

更新日期：2005-07-01 00:00:00

abstract：:Obesity is a highly prevalent complex trait that raises the risk of other chronic diseases such as type 2 diabetes, certain cancers, sleep apnea, and cardiovascular disease, and shortens lifespan. Clinical intervention studies focused on weight loss and epidemiological studies of obesity indicate that genetic variatio...

journal_title：Current vascular pharmacology

authors： Franks PW,Poveda A

更新日期：2011-07-01 00:00:00

abstract：BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, dat...

journal_title：Current vascular pharmacology

authors： Imprialos K,Stavropoulos K,Bouloukou S,Kerpiniotis G,Karagiannis A,Doumas M

更新日期：2018-01-01 00:00:00

abstract：:Alterations of fibroblast growth factor 23 (FGF-23) and Klotho levels are considered to be the earliest biochemical abnormality of chronic kidney disease - mineral and bone disease (CKDMBD) syndrome. Moreover, emerging data suggests that the dysregulated FGF-23 and Klotho axis has many effects on the cardiovascular (C...

journal_title：Current vascular pharmacology

authors： Memmos E,Papagianni A

更新日期：2021-01-01 00:00:00

abstract：UNLABELLED:Hif-1α, a master regulator of ischemia-responsive gene induction, controls pro-angiogenic gene expression of VEGF-A, flt-1, IGF-1 and erythropoietin, rendering its overexpression an attractive tool for therapeutic neovascularization. Utilizing an adenoviral vector system, we investigated the efficacy of sele...

journal_title：Current vascular pharmacology

authors： Hinkel R,Lebherz C,Fydanaki M,Wuchrer A,El-Aouni C,Thormann M,Thein E,Kupatt C,Boekstegers P

更新日期：2013-01-01 00:00:00

abstract：:This review provides evidence that antenatal hypoxia, which represents a significant and worldwide problem, causes prenatal programming of the lung. A general overview of lung development is provided along with some background regarding transcriptional and signaling systems of the lung. The review illustrates that ant...

journal_title：Current vascular pharmacology

authors： Papamatheakis DG,Blood AB,Kim JH,Wilson SM

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. METHOD:A multicentre, non-interventional survey conducted in 6 Middle Eastern cou...

journal_title：Current vascular pharmacology

authors： Shehab A,Al-Rasadi K,Arafah M,Al-Hinai AT,Al Mahmeed W,Bhagavathula AS,Al Tamimi O,Al Herz S,Al Anazi F,Al Nemer K,Metwally O,Alkhadra A,Fakhry M,Elghetany H,Medani AR,Yusufali AH,Al Jassim O,Al Hallaq O,Baslaib FOAS

更新日期：2018-01-01 00:00:00